Prothena Corp Public (PRTA) Total Non-Current Liabilities (2013 - 2026)

Prothena Corp Public's (PRTA) quarterly Total Non-Current Liabilities came in at $4.8 million in Q1 2026, down 48.23% year-on-year from $9.2 million in Q1 2025, and down 13.23% quarter-over-quarter from $5.5 million in Q4 2025.

Prothena Corp Public (PRTA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

Prothena Corp Public's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $4.8 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 48.23% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 48.23% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, down 53.03% from the prior year.
  • Total Non-Current Liabilities declined to $4.8 million in Q1 2026 per PRTA's latest filing, from $5.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $106.0 million in Q1 2022 and bottomed at $4.8 million in Q1 2026.
  • The 5-year median for Total Non-Current Liabilities is $67.4 million (2023), against an average of $50.2 million.
  • Across the five-year window, Total Non-Current Liabilities increased 7.25% in 2022 and plunged 88.14% in 2025, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $85.8 million in 2022, then dropped by 8.99% to $78.1 million in 2023, then slumped by 85.05% to $11.7 million in 2024, then plunged by 53.03% to $5.5 million in 2025, then slipped by 13.23% to $4.8 million in 2026.
  • Per Business Quant, the three latest PRTA Total Non-Current Liabilities figures stand at $4.8 million (Q1 2026), $5.5 million (Q4 2025), and $6.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Prothena Corp Public 458.13 Mn 128.67 Mn - 4.76 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.76 Mn
Dec 31, 2025 5.49 Mn
Sep 30, 2025 6.20 Mn
Jun 30, 2025 6.93 Mn
Mar 31, 2025 9.20 Mn
Dec 31, 2024 11.68 Mn
Sep 30, 2024 14.47 Mn
Jun 30, 2024 16.90 Mn
Mar 31, 2024 77.53 Mn
Dec 31, 2023 78.13 Mn
Sep 30, 2023 76.32 Mn
Jun 30, 2023 67.41 Mn
Mar 31, 2023 85.29 Mn
Dec 31, 2022 85.85 Mn
Sep 30, 2022 99.19 Mn
Jun 30, 2022 102.18 Mn
Mar 31, 2022 106.03 Mn
Dec 31, 2021 109.87 Mn
Sep 30, 2021 113.03 Mn
Jun 30, 2021 95.27 Mn